Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas
Open Access
- 8 June 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (27) , 42553-42565
Abstract
Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomasKeywords
This publication has 37 references indexed in Scilit:
- Mucins in pancreatic cancer and its microenvironmentNature Reviews Gastroenterology & Hepatology, 2013
- Japan Pancreatic Cancer Registry; 30th Year AnniversaryPancreas, 2012
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cellsBritish Journal of Cancer, 2008
- Emerging Roles of MUC4 in Cancer: A Novel Target for Diagnosis and TherapyCancer Research, 2007
- A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-β in pancreatic carcinogenesisOncogene, 2004
- Classification of Pancreatic CancerPancreas, 2004
- Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and MetastasisCancer Research, 2004
- Mucins in cancer: protection and control of the cell surfaceNature Reviews Cancer, 2004
- Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathwaysOncogene, 2002